Moderna announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 in children and adolescents 6 to 17 years of age. The authorizations are based on a 25 undefined booster dose for children ages 6 to 11 years old and a 50 undefined booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized COVID-19 vaccines or a previous booster. The pediatric and adolescent authorization is based on clinical trial booster data for Moderna’s original vaccine, Spikevax, which was administered to over a thousand participants in each cohort. The application described data from a 25 undefined booster dose administered to children ages 6 to 11 years old and a 50 undefined booster dose for adolescents 12 to 17 years old, following a completed primary series of the Moderna COVID-19 vaccine. In addition, the application included clinical trial data from a Phase 2/3 studying mRNA-1273.214.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Moderna Tanks on Phase 3 Data in Seasonal Influenza
- Jefferies says Moderna flu vaccine data doesn’t change improving pipeline thesis
- Moderna plans to keep COVID vaccine free for consumers, ABC News says
- Sanders calls Moderna chief to testify on vaccine price hike plans, WP says
- Model N price target raised to $52 from $45 at Truist